

Gene Therapy Market by Vectors (Non-viral(Oligonucleotides), Viral(Retroviral, Adeno-associated)), Indication (Cancer, Neurological, Hepatological Diseases, Duchenne Muscular Dystrophy), Delivery Method (In Vivo, Ex Vivo), Region - Global Forecast to 2027

Market Report | 2022-07-27 | 154 pages | MarketsandMarkets

AVAILABLE LICENSES:

- Single User \$4950.00
- Multi User \$6650.00
- Corporate License \$8150.00
- Enterprise Site License \$10000.00

Report description:

The global gene therapy market is valued at an estimated USD 7.3 billion in 2022 and is projected to reach USD 17.2 billion by 2027, at a CAGR of 18.6% during the forecast period. Factors such as rising cases of neurological diseases and cancer, growing gene therapy product approvals, and increasing investment in gene therapy related research and development drive the market growth. However, factors like high cost of gene therapy is restraining the growth of this market.

"The cancer segment accounted for the highest growth rate in the gene therapy market, by indication, during the forecast period" In 2021, cancer segment accounted for the highest growth rate. Growing disease burden of cancer across the globe coupled with rising demand for gene therapies to treat cancer will augment the segmental growth of cancer over the forecast period.

"Asia Pacific: The fastest-growing region in the gene therapy market"

The Asia Pacific market is estimated to record the highest CAGR during the forecast period. The high growth rate of this market can be attributed to the improving healthcare expenditure in emerging economies, increasing product launches, and increasing incidence of cancer and neurological diseases.

The primary interviews conducted for this report can be categorized as follows:

- By Company Type: Tier 1- 32%, Tier 2- 44%, and Tier 3-24%
- By Designation: C-level (Managers) - 30%, D-level(CXOs, Directors)- 34%, and Others (Executives) - 36%
- By Region: North America -50%, Europe -32%, Asia-Pacific -10%, Rest of the World -8%

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

List of Companies Profiled in the Report:

- [] Biogen (US)
- [] Sarepta Therapeutics (US)
- [] Gilead Sciences, Inc. (US)
- [] Amgen, Inc. (US)
- [] Novartis AG (Switzerland)
- [] Orchard Therapeutics Plc (UK)
- [] Spark Therapeutics, Inc. (A Part Of ?F. Hoffmann-La Roche) (US)
- [] AGC Biologics (US)
- [] Angen, Inc. (Japan)
- [] Bluebird Bio, Inc. (US)
- [] Jazz Pharmaceuticals Plc (Ireland)
- [] Dynavax Technologies (US)
- [] Human Stem Cells Institute (Russia)
- [] SibionoGenetech Co., Ltd. (China)
- [] Shanghai Sunway Biotech Co., Ltd. (China)
- [] Uniqure N.V. (Netherland)
- [] Gensight Biologics S.A. (France)
- [] Celgene Corporation (A Bristol-Myers Squibb Company) (US)
- [] Ccollectis (France)
- [] Sangamo Therapeutics (US)
- [] Mustang Bio (US)
- [] AGTC (Applied Genetic Technologies Corporation) (US)
- [] Poseida Therapeutics, Inc. (US)

Research Coverage:

This report provides a detailed picture of the global gene therapy market. It aims at estimating the size and future growth potential of the market across different segments such as vectors, indication, delivery method, and region. The report also includes an in-depth competitive analysis of the key market players along with their company profiles recent developments and key market strategies.

Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall gene therapy market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, challenges, trends, and opportunities.

Table of Contents:

1 [] INTRODUCTION []	23
1.1 [] STUDY OBJECTIVES []	23
1.2 [] MARKET DEFINITION []	23
1.2.1 [] INCLUSIONS AND EXCLUSIONS []	23
1.3 [] STUDY SCOPE []	24
1.3.1 [] MARKETS COVERED []	24
1.4 [] YEARS CONSIDERED []	24
1.5 [] CURRENCY CONSIDERED []	25
1.6 [] LIMITATIONS []	25

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

1.7	STAKEHOLDERS	25
1.8	SUMMARY OF CHANGES	25
2	RESEARCH METHODOLOGY	26
2.1	RESEARCH DATA	26
FIGURE 1	RESEARCH DESIGN	26
2.1.1	SECONDARY DATA	26
FIGURE 2	KEY DATA FROM SECONDARY SOURCES	27
2.1.2	PRIMARY DATA	27
FIGURE 3	BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION	28
2.2	MARKET SIZE ESTIMATION	28
2.2.1	BOTTOM-UP APPROACH	28
2.2.2	COMPANY REVENUE ANALYSIS	28
FIGURE 4	COMPANY REVENUE ANALYSIS	29
2.2.3	GROWTH FORECAST	29
2.3	MARKET BREAKDOWN AND DATA TRIANGULATION	30
FIGURE 5	DATA TRIANGULATION METHODOLOGY	30
2.4	RESEARCH ASSUMPTIONS	31
2.5	RISK ASSESSMENT	31
3	EXECUTIVE SUMMARY	32
FIGURE 6	GENE THERAPY MARKET, BY VECTOR, 2022 VS. 2027 (USD MILLION)	32
FIGURE 7	GENE THERAPY MARKET, BY DELIVERY METHOD, 2022 VS. 2027 (USD MILLION)	33
FIGURE 8	GENE THERAPY MARKET, BY INDICATION, 2022 VS. 2027 (USD MILLION)	33
FIGURE 9	GENE THERAPY MARKET: REGIONAL SNAPSHOT	34
?		
4	PREMIUM INSIGHTS	35
4.1	GENE THERAPY MARKET OVERVIEW	35
FIGURE 10	HIGH INCIDENCE OF CANCER & OTHER TARGETED DISEASES TO DRIVE MARKET GROWTH	35
4.2	NORTH AMERICA: GENE THERAPY MARKET, BY VECTOR (2021)	36
FIGURE 11	NON-VIRAL VECTORS DOMINATE NORTH AMERICAN GENE THERAPY MARKET	36
4.3	GEOGRAPHICAL SNAPSHOT OF THE GENE THERAPY MARKET	36
FIGURE 12	APAC COUNTRIES TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD	36
5	MARKET OVERVIEW	37
5.1	INTRODUCTION	37
5.2	MARKET DYNAMICS	37
FIGURE 13	GENE THERAPY MARKET: DRIVERS, OPPORTUNITIES, AND CHALLENGES	37
5.2.1	DRIVERS	37
5.2.1.1	High incidence of cancer and other target diseases	37
TABLE 1	NUMBER OF NEW CANCER CASES, 2020 VS. 2025	38
5.2.1.2	Product approvals	38
TABLE 2	PRODUCT APPROVALS, 2015-2021	38
5.2.1.3	Funding for gene therapy research	39
5.2.2	OPPORTUNITIES	39
5.2.2.1	Strong product pipeline	39
TABLE 3	GENE THERAPY MARKET: INDICATIVE LIST OF PIPELINE DRUGS	40
5.2.3	CHALLENGES	40
5.2.3.1	High treatment costs	40

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

TABLE 4	PRICE OF GENE THERAPY PRODUCTS, 2021	40
5.3	PRICING ANALYSIS	41
5.4	TECHNOLOGY ANALYSIS	41
FIGURE 14	KEY STEPS IN GENE THERAPY	41
5.5	SUPPLY CHAIN ANALYSIS	42
5.5.1	PROMINENT COMPANIES	42
5.5.2	SMALL AND MEDIUM-SIZED ENTERPRISES (SMES)	42
5.5.3	END USERS	42
FIGURE 15	GENE THERAPY MARKET: SUPPLY CHAIN ANALYSIS	42
5.6	ECOSYSTEM ANALYSIS OF GENE THERAPY MARKET	43
TABLE 5	STAKEHOLDERS IN THE GENE THERAPY ECOSYSTEM AND THEIR ROLES	43
5.7	KEY CONFERENCES AND EVENTS IN 2022-2023	44
TABLE 6	GENE THERAPY MARKET: DETAILED LIST OF CONFERENCES AND EVENTS	44
5.8	REGULATORY ANALYSIS	45
TABLE 7	NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS	45
TABLE 8	EUROPE: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS	45
TABLE 9	ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS	46
TABLE 10	REST OF THE WORLD: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS	46
5.9	PORTER'S FIVE FORCES ANALYSIS	46
TABLE 11	GENE THERAPY MARKET: PORTER'S FIVE FORCES ANALYSIS	46
5.9.1	THREAT OF NEW ENTRANTS	47
5.9.2	THREAT OF SUBSTITUTES	47
5.9.3	BARGAINING POWER OF SUPPLIERS	47
5.9.4	BARGAINING POWER OF BUYERS	47
5.9.5	COMPETITIVE RIVALRY AMONG EXISTING PLAYERS	47
5.10	KEY STAKEHOLDERS AND BUYING CRITERIA	47
5.10.1	KEY STAKEHOLDERS IN BUYING PROCESS	47
FIGURE 16	INFLUENCE OF STAKEHOLDERS IN BUYING PROCESS OF GENE THERAPY PRODUCTS	47
5.10.2	BUYING CRITERIA FOR GENE THERAPY PRODUCTS	48
FIGURE 17	KEY BUYING CRITERIA FOR END USERS	48
6	GENE THERAPY MARKET, BY VECTOR	49
6.1	INTRODUCTION	50
TABLE 12	GENE THERAPY MARKET, BY VECTOR, 2020-2027 (USD MILLION)	50
6.2	NON-VIRAL VECTORS	50
TABLE 13	GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY REGION, 2020-2027 (USD MILLION)	50
TABLE 14	GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY TYPE, 2020-2027 (USD MILLION)	51
6.2.1	OLIGONUCLEOTIDES	51
6.2.1.1	Oligonucleotides account for the largest share of the non-viral vectors market	51
TABLE 15	GENE THERAPY MARKET FOR OLIGONUCLEOTIDES, BY REGION, 2020-2027 (USD MILLION)	51
6.2.2	OTHER NON-VIRAL VECTORS	52
TABLE 16	GENE THERAPY MARKET FOR OTHER NON-VIRAL VECTORS, BY REGION, 2020-2027 (USD MILLION)	52
6.3	VIRAL VECTORS	52
TABLE 17	GENE THERAPY MARKET FOR VIRAL VECTORS, BY REGION, 2020-2027 (USD MILLION)	52

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

TABLE 18 GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE,
2020-2027 (USD MILLION) 53

6.3.1 RETROVIRAL VECTORS 53

TABLE 19 GENE THERAPY MARKET FOR RETROVIRAL VECTORS, BY REGION,
2020-2027 (USD MILLION) 53

TABLE 20 GENE THERAPY MARKET FOR RETROVIRAL VECTORS, BY TYPE,
2020-2027 (USD MILLION) 53

?

6.3.1.1 Gamma-retroviral vectors 54

6.3.1.1.1 Availability of wide range of gamma-retroviral vectors supports market growth 54

TABLE 21 GENE THERAPY MARKET FOR GAMMA-RETROVIRAL VECTORS, BY REGION, 2020-2027 (USD MILLION) 54

6.3.1.2 Lentiviral vectors 54

6.3.1.2.1 North America to dominate lentiviral vectors market 54

TABLE 22 GENE THERAPY MARKET FOR LENTIVIRAL VECTORS, BY REGION,
2020-2027 (USD MILLION) 54

6.3.2 ADENO-ASSOCIATED VIRUS VECTORS 55

6.3.2.1 Potential applications in in vivo applications to drive interest in AAV vectors 55

TABLE 23 GENE THERAPY MARKET FOR AAV VECTORS, BY REGION,
2020-2027 (USD MILLION) 55

6.3.3 OTHER VIRAL VECTORS 55

TABLE 24 GENE THERAPY MARKET FOR OTHER VIRAL VECTORS, BY REGION,
2020-2027 (USD MILLION) 55

7 GENE THERAPY MARKET, BY INDICATION 56

7.1 INTRODUCTION 57

TABLE 25 GENE THERAPY MARKET, BY INDICATION, 2020-2027 (USD MILLION) 57

7.2 NEUROLOGICAL DISEASES 57

7.2.1 NEUROLOGICAL DISEASES TO FORM THE LARGEST INDICATION SEGMENT IN THIS MARKET 57

TABLE 26 GENE THERAPY MARKET FOR NEUROLOGICAL DISEASES, BY REGION,
2020-2027 (USD MILLION) 58

7.3 CANCER 58

7.3.1 GROWING DEMAND FOR CANCER THERAPIES TO DRIVE MARKET GROWTH 58

TABLE 27 NUMBER OF NEW CANCER CASES, BY TYPE, 2020-2040 58

TABLE 28 GENE THERAPY MARKET FOR CANCER, BY REGION,
2020-2027 (USD MILLION) 59

7.4 DUCHENNE MUSCULAR DYSTROPHY 60

7.4.1 RISING PREVALENCE OF DMD TO SUPPORT MARKET GROWTH 60

TABLE 29 GENE THERAPY MARKET FOR DMD, BY REGION, 2020-2027 (USD MILLION) 60

7.5 HEPATOLOGICAL DISEASES 60

7.5.1 INCREASING PREVALENCE OF HEPATITIS B INFECTIONS TO SUPPORT MARKET GROWTH 60

TABLE 30 GENE THERAPY MARKET FOR HEPATOLOGICAL DISEASES, BY REGION,
2020-2027 (USD MILLION) 60

7.6 OTHER INDICATIONS 61

TABLE 31 GENE THERAPY MARKET FOR OTHER INDICATIONS, BY REGION,
2020-2027 (USD MILLION) 61

?

8 GENE THERAPY MARKET, BY DELIVERY METHOD 62

8.1 INTRODUCTION 63

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

TABLE 32 □ GENE THERAPY MARKET, BY DELIVERY METHOD, 2020-2027 (USD MILLION) □ 63

8.2 □ IN VIVO GENE THERAPY □ 63

8.2.1 □ IN VIVO GENE THERAPY TO DOMINATE MARKET □ 63

TABLE 33 □ IN VIVO GENE THERAPY MARKET, BY REGION, 2020-2027 (USD MILLION) □ 63

8.3 □ EX VIVO GENE THERAPY □ 64

8.3.1 □ EX VIVO GENE THERAPY SEGMENT TO WITNESS HIGH GROWTH □ 64

TABLE 34 □ EX VIVO GENE THERAPY MARKET, BY REGION, 2020-2027 (USD MILLION) □ 64

9 □ GENE THERAPY MARKET, BY REGION □ 65

9.1 □ INTRODUCTION □ 66

TABLE 35 □ GENE THERAPY MARKET, BY REGION, 2020-2027 (USD MILLION) □ 66

9.2 □ NORTH AMERICA □ 67

FIGURE 18 □ NORTH AMERICA: GENE THERAPY MARKET SNAPSHOT □ 67

TABLE 36 □ NORTH AMERICA: GENE THERAPY MARKET, BY COUNTRY, 2020-2027 (USD MILLION) □ 68

TABLE 37 □ NORTH AMERICA: GENE THERAPY MARKET, BY VECTOR, 2020-2027 (USD MILLION) □ 68

TABLE 38 □ NORTH AMERICA: GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY TYPE, 2020-2027 (USD MILLION) □ 68

TABLE 39 □ NORTH AMERICA: GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE, 2020-2027 (USD MILLION) □ 68

TABLE 40 □ NORTH AMERICA: RETROVIRAL VECTORS MARKET, BY TYPE, 2020-2027 (USD MILLION) □ 69

TABLE 41 □ NORTH AMERICA: GENE THERAPY MARKET, BY DELIVERY METHOD, 2020-2027 (USD MILLION) □ 69

TABLE 42 □ NORTH AMERICA: GENE THERAPY MARKET, BY INDICATION, 2020-2027 (USD MILLION) □ 69

9.2.1 □ US □ 70

9.2.1.1 □ US dominates the global gene therapy market □ 70

TABLE 43 □ LIST OF GENE THERAPY PIPELINE CANDIDATES OF US-BASED COMPANIES □ 70

TABLE 44 □ US FDA GENE THERAPY PRODUCT APPROVALS □ 71

TABLE 45 □ US: GENE THERAPY MARKET, BY VECTOR, 2020-2027 (USD MILLION) □ 71

TABLE 46 □ US: GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY TYPE, 2020-2027 (USD MILLION) □ 71

TABLE 47 □ US: GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE, 2020-2027 (USD MILLION) □ 72

TABLE 48 □ US: RETROVIRAL VECTORS MARKET, BY TYPE, 2020-2027 (USD MILLION) □ 72

TABLE 49 □ US: GENE THERAPY MARKET, BY DELIVERY METHOD, 2020-2027 (USD MILLION) □ 72

TABLE 50 □ US: GENE THERAPY MARKET, BY INDICATION, 2020-2027 (USD MILLION) □ 72

9.2.2 □ CANADA □ 73

9.2.2.1 □ Growing burden of cancer supports market growth in Canada □ 73

TABLE 51 □ CANADA: GENE THERAPY MARKET, BY VECTOR, 2020-2027 (USD MILLION) □ 73

TABLE 52 □ CANADA: GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY TYPE, 2020-2027 (USD MILLION) □ 73

TABLE 53 □ CANADA: GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE, 2020-2027 (USD MILLION) □ 74

TABLE 54 □ CANADA: RETROVIRAL VECTORS MARKET, BY TYPE, 2020-2027 (USD MILLION) □ 74

TABLE 55 □ CANADA: GENE THERAPY MARKET, BY DELIVERY METHOD,

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

2020-2027 (USD MILLION) 74

TABLE 56 CANADA: GENE THERAPY MARKET, BY INDICATION,

2020-2027 (USD MILLION) 75

9.3 EUROPE 75

TABLE 57 EUROPE: GENE THERAPY MARKET, BY COUNTRY, 2020-2027 (USD MILLION) 75

TABLE 58 EUROPE: GENE THERAPY MARKET, BY VECTOR, 2020-2027 (USD MILLION) 76

TABLE 59 EUROPE: GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY TYPE,

2020-2027 (USD MILLION) 76

TABLE 60 EUROPE: GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE,

2020-2027 (USD MILLION) 76

TABLE 61 EUROPE: RETROVIRAL VECTORS MARKET, BY TYPE,

2020-2027 (USD MILLION) 76

TABLE 62 EUROPE: GENE THERAPY MARKET, BY DELIVERY METHOD,

2020-2027 (USD MILLION) 77

TABLE 63 EUROPE: GENE THERAPY MARKET, BY INDICATION,

2020-2027 (USD MILLION) 77

9.3.1 GERMANY 77

9.3.1.1 Germany dominates European gene therapy market 77

TABLE 64 GERMANY: CANCER INCIDENCE, BY TYPE, 2020 VS. 2040 77

TABLE 65 GERMANY: GENE THERAPY MARKET, BY VECTOR, 2020-2027 (USD MILLION) 78

TABLE 66 GERMANY: GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY TYPE, 2020-2027 (USD MILLION) 78

TABLE 67 GERMANY: GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE,

2020-2027 (USD MILLION) 79

TABLE 68 GERMANY: RETROVIRAL VECTORS MARKET, BY TYPE,

2020-2027 (USD MILLION) 79

TABLE 69 GERMANY: GENE THERAPY MARKET, BY DELIVERY METHOD,

2020-2027 (USD MILLION) 79

TABLE 70 GERMANY: GENE THERAPY MARKET, BY INDICATION,

2020-2027 (USD MILLION) 79

9.3.2 FRANCE 80

9.3.2.1 Increasing cancer incidence to support market growth 80

TABLE 71 FRANCE: CANCER INCIDENCE, BY TYPE, 2020 VS. 2040 80

TABLE 72 FRANCE: GENE THERAPY MARKET, BY VECTOR, 2020-2027 (USD MILLION) 80

TABLE 73 FRANCE: GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY TYPE,

2020-2027 (USD MILLION) 80

TABLE 74 FRANCE: GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE,

2020-2027 (USD MILLION) 81

TABLE 75 FRANCE: RETROVIRAL VECTORS MARKET, BY TYPE,

2020-2027 (USD MILLION) 81

TABLE 76 FRANCE: GENE THERAPY MARKET, BY DELIVERY METHOD,

2020-2027 (USD MILLION) 81

TABLE 77 FRANCE: GENE THERAPY MARKET, BY INDICATION,

2020-2027 (USD MILLION) 81

9.3.3 UK 82

9.3.3.1 Rising incidence of melanoma to support market growth in UK 82

TABLE 78 UK: CANCER INCIDENCE, BY TYPE, 2020 VS. 2040 82

TABLE 79 UK: GENE THERAPY MARKET, BY VECTOR, 2020-2027 (USD MILLION) 82

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

TABLE 80 UK: GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY TYPE, 2020-2027 (USD MILLION) 83

TABLE 81 UK: GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE, 2020-2027 (USD MILLION) 83

TABLE 82 UK: RETROVIRAL VECTORS MARKET, BY TYPE, 2020-2027 (USD MILLION) 83

TABLE 83 UK: GENE THERAPY MARKET, BY DELIVERY METHOD, 2020-2027 (USD MILLION) 83

TABLE 84 UK: GENE THERAPY MARKET, BY INDICATION, 2020-2027 (USD MILLION) 84

9.3.4 ITALY 84

9.3.4.1 High incidence of targeted diseases and increasing healthcare spending to drive Italian market growth 84

TABLE 85 ITALY: CANCER INCIDENCE, BY TYPE, 2020 VS. 2040 84

TABLE 86 ITALY: GENE THERAPY MARKET, BY VECTOR, 2020-2027 (USD MILLION) 84

TABLE 87 ITALY: GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY TYPE, 2020-2027 (USD MILLION) 85

TABLE 88 ITALY: GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE, 2020-2027 (USD MILLION) 85

TABLE 89 ITALY: RETROVIRAL VECTORS MARKET, BY TYPE, 2020-2027 (USD MILLION) 85

TABLE 90 ITALY: GENE THERAPY MARKET, BY DELIVERY METHOD, 2020-2027 (USD MILLION) 85

TABLE 91 ITALY: GENE THERAPY MARKET, BY INDICATION, 2020-2027 (USD MILLION) 86

9.3.5 SPAIN 86

9.3.5.1 Rising cancer incidence and increasing healthcare expenditure to support market growth in Spain 86

TABLE 92 SPAIN: CANCER INCIDENCE, BY TYPE, 2020 VS. 2040 86

TABLE 93 SPAIN: GENE THERAPY MARKET, BY VECTOR, 2020-2027 (USD MILLION) 86

TABLE 94 SPAIN: GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY TYPE, 2020-2027 (USD MILLION) 87

TABLE 95 SPAIN: GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE, 2020-2027 (USD MILLION) 87

TABLE 96 SPAIN: RETROVIRAL VECTORS MARKET, BY TYPE, 2020-2027 (USD MILLION) 87

TABLE 97 SPAIN: GENE THERAPY MARKET, BY DELIVERY METHOD, 2020-2027 (USD MILLION) 87

TABLE 98 SPAIN: GENE THERAPY MARKET, BY INDICATION, 2020-2027 (USD MILLION) 88

9.3.6 REST OF EUROPE 88

TABLE 99 ROE: GENE THERAPY MARKET, BY VECTOR, 2020-2027 (USD MILLION) 88

TABLE 100 ROE: GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY TYPE, 2020-2027 (USD MILLION) 89

TABLE 101 ROE: GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE, 2020-2027 (USD MILLION) 89

TABLE 102 ROE: RETROVIRAL VECTORS MARKET, BY TYPE, 2020-2027 (USD MILLION) 89

TABLE 103 ROE: GENE THERAPY MARKET, BY DELIVERY METHOD, 2020-2027 (USD MILLION) 89

TABLE 104 ROE: GENE THERAPY MARKET, BY INDICATION, 2020-2027 (USD MILLION) 90

9.4 ASIA PACIFIC 91

FIGURE 19 ASIA PACIFIC: GENE THERAPY MARKET SNAPSHOT 91

TABLE 105 ASIA PACIFIC: GENE THERAPY MARKET, BY COUNTRY, 2020-2027 (USD MILLION) 92

TABLE 106 ASIA PACIFIC: GENE THERAPY MARKET, BY VECTOR,

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

2020-2027 (USD MILLION) 92

TABLE 107 ASIA PACIFIC: GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY TYPE, 2020-2027 (USD MILLION) 92

TABLE 108 ASIA PACIFIC: GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE,

2020-2027 (USD MILLION) 92

TABLE 109 ASIA PACIFIC: RETROVIRAL VECTORS MARKET, BY TYPE,

2020-2027 (USD MILLION) 93

TABLE 110 ASIA PACIFIC: GENE THERAPY MARKET, BY DELIVERY METHOD,

2020-2027 (USD MILLION) 93

TABLE 111 ASIA PACIFIC: GENE THERAPY MARKET, BY INDICATION,

2020-2027 (USD MILLION) 93

9.4.1 JAPAN 94

9.4.1.1 Japan dominates the APAC gene therapy market 94

TABLE 112 JAPAN: CANCER INCIDENCE, BY TYPE, 2020 VS. 2040 94

TABLE 113 JAPAN: GENE THERAPY MARKET, BY VECTOR, 2020-2027 (USD MILLION) 94

TABLE 114 JAPAN: GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY TYPE,

2020-2027 (USD MILLION) 94

TABLE 115 JAPAN: GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE,

2020-2027 (USD MILLION) 95

TABLE 116 JAPAN: RETROVIRAL VECTORS MARKET, BY TYPE, 2020-2027 (USD MILLION) 95

TABLE 117 JAPAN: GENE THERAPY MARKET, BY DELIVERY METHOD,

2020-2027 (USD MILLION) 95

TABLE 118 JAPAN: GENE THERAPY MARKET, BY INDICATION, 2020-2027 (USD MILLION) 95

9.4.2 CHINA 96

9.4.2.1 Rising prevalence of cancer and established base for gene therapy to support market growth in China 96

TABLE 119 CHINA: CANCER INCIDENCE, BY TYPE, 2020 VS. 2040 96

TABLE 120 CHINA: GENE THERAPY MARKET, BY VECTOR, 2020-2027 (USD MILLION) 96

TABLE 121 CHINA: GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY TYPE,

2020-2027 (USD MILLION) 96

TABLE 122 CHINA: GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE,

2020-2027 (USD MILLION) 97

TABLE 123 CHINA: RETROVIRAL VECTORS MARKET, BY TYPE, 2020-2027 (USD MILLION) 97

TABLE 124 CHINA: GENE THERAPY MARKET, BY DELIVERY METHOD,

2020-2027 (USD MILLION) 97

TABLE 125 CHINA: GENE THERAPY MARKET, BY INDICATION, 2020-2027 (USD MILLION) 97

9.4.3 REST OF ASIA PACIFIC 98

TABLE 126 ROAPAC: GENE THERAPY MARKET, BY VECTOR, 2020-2027 (USD MILLION) 98

TABLE 127 ROAPAC: GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY TYPE,

2020-2027 (USD MILLION) 98

TABLE 128 ROAPAC: GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE,

2020-2027 (USD MILLION) 98

TABLE 129 ROAPAC: RETROVIRAL VECTORS MARKET, BY TYPE,

2020-2027 (USD MILLION) 99

TABLE 130 ROAPAC: GENE THERAPY MARKET, BY DELIVERY METHOD,

2020-2027 (USD MILLION) 99

TABLE 131 ROAPAC: GENE THERAPY MARKET, BY INDICATION,

2020-2027 (USD MILLION) 99

9.5 REST OF THE WORLD 100

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

TABLE 132 □ ROW: GENE THERAPY MARKET, BY VECTOR, 2020-2027 (USD MILLION) □ 100

TABLE 133 □ ROW: GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY TYPE, 2020-2027 (USD MILLION) □ 100

TABLE 134 □ ROW: GENE THERAPY MARKET, BY DELIVERY METHOD, 2020-2027 (USD MILLION) □ 100

TABLE 135 □ ROW: GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE, 2020-2027 (USD MILLION) □ 101

TABLE 136 □ ROW: RETROVIRAL VECTORS MARKET, BY TYPE, 2020-2027 (USD MILLION) □ 101

TABLE 137 □ ROW: GENE THERAPY MARKET, BY INDICATION, 2020-2027 (USD MILLION) □ 101

10 □ COMPETITIVE LANDSCAPE □ 102

10.1 □ OVERVIEW □ 102

FIGURE 20 □ KEY DEVELOPMENTS IN THE GENE THERAPY MARKET □ 102

10.2 □ MARKET SHARE ANALYSIS, 2021 □ 103

FIGURE 21 □ GENE THERAPY MARKET SHARE ANALYSIS, 2021 □ 103

TABLE 138 □ GENE THERAPY MARKET: DEGREE OF COMPETITION □ 104

10.3 □ REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS □ 104

FIGURE 22 □ REVENUE SHARE ANALYSIS OF TOP PLAYERS IN GENE THERAPY, 2019-2021 □ 104

10.4 □ COMPANY EVALUATION QUADRANT □ 105

10.4.1 □ STARS □ 105

10.4.2 □ EMERGING LEADERS □ 105

10.4.3 □ PERVASIVE PLAYERS □ 105

10.4.4 □ PARTICIPANTS □ 105

FIGURE 23 □ GENE THERAPY MARKET: COMPANY EVALUATION QUADRANT, 2021 □ 106

10.5 □ COMPANY FOOTPRINT ANALYSIS □ 107

10.5.1 □ PRODUCT FOOTPRINT OF COMPANIES □ 107

TABLE 139 □ GENE THERAPY MARKET: COMPANY PRODUCT FOOTPRINT (2021) ACROSS INDICATIONS □ 107

10.6 □ COMPETITIVE SCENARIO □ 108

TABLE 140 □ PRODUCT APPROVALS, 2018-2022 □ 108

TABLE 141 □ DEALS, 2018-2022 □ 108

TABLE 142 □ OTHER DEVELOPMENTS, 2018-2022 □ 109

11 □ COMPANY PROFILES □ 110

(Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments)*

11.1 □ BIOGEN □ 110

TABLE 143 □ BIOGEN: BUSINESS OVERVIEW □ 110

FIGURE 24 □ BIOGEN: COMPANY SNAPSHOT □ 110

11.2 □ SAREPTA THERAPEUTICS □ 113

TABLE 144 □ SAREPTA THERAPEUTICS: BUSINESS OVERVIEW □ 113

FIGURE 25 □ SAREPTA THERAPEUTICS: COMPANY SNAPSHOT □ 113

11.3 □ GILEAD SCIENCES, INC. □ 117

TABLE 145 □ GILEAD SCIENCES INC: BUSINESS OVERVIEW □ 117

FIGURE 26 □ GILEAD SCIENCES, INC.: COMPANY SNAPSHOT □ 118

11.4 □ AMGEN, INC. □ 120

TABLE 146 □ AMGEN INC: BUSINESS OVERVIEW □ 120

FIGURE 27 □ AMGEN, INC.: COMPANY SNAPSHOT □ 121

11.5 □ NOVARTIS AG □ 123

TABLE 147 □ NOVARTIS AG: BUSINESS OVERVIEW □ 123

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

FIGURE 28	NOVARTIS AG: COMPANY SNAPSHOT	124
11.6	ORCHARD THERAPEUTICS PLC	127
TABLE 148	ORCHARD THERAPEUTICS PLC: BUSINESS OVERVIEW	127
FIGURE 29	ORCHARD THERAPEUTICS PLC: COMPANY SNAPSHOT	127
11.7	SPARK THERAPEUTICS, INC. (AN F. HOFFMANN-LA ROCHE COMPANY)	129
TABLE 149	SPARK THERAPEUTICS INC: BUSINESS OVERVIEW	129
11.8	AGC BIOLOGICS	131
TABLE 150	AGC BIOLOGICS: BUSINESS OVERVIEW	131
11.9	ANGES, INC.	132
TABLE 151	ANGES INC: BUSINESS OVERVIEW	132
FIGURE 30	ANGES, INC.: COMPANY SNAPSHOT	132
11.10	BLUEBIRD BIO, INC.	134
TABLE 152	BLUEBIRD BIO: BUSINESS OVERVIEW	134
FIGURE 31	BLUEBIRD BIO: COMPANY SNAPSHOT	134
11.11	JAZZ PHARMACEUTICALS PLC	136
TABLE 153	JAZZ PHARMACEUTICALS: BUSINESS OVERVIEW	136
FIGURE 32	JAZZ PHARMACEUTICALS PLC: COMPANY SNAPSHOT	137
11.12	DYNAVAX TECHNOLOGIES	139
TABLE 154	DYNAVAX TECHNOLOGIES: BUSINESS OVERVIEW	139
FIGURE 33	DYNAVAX TECHNOLOGIES: COMPANY SNAPSHOT	140
11.13	HUMAN STEM CELLS INSTITUTE	141
TABLE 155	HUMAN STEM CELLS INSTITUTE: BUSINESS OVERVIEW	141
11.14	SIBIONO GENETECH CO., LTD.	142
TABLE 156	SIBIONO GENETECH CO LTD: BUSINESS OVERVIEW	142
11.15	SHANGHAI SUNWAY BIOTECH CO., LTD.	143
TABLE 157	SHANGHAI SUNWAY BIOTECH CO LTD: BUSINESS OVERVIEW	143
11.16	UNIQUE N.V.	144
TABLE 158	UNIQUE NV: BUSINESS OVERVIEW	144
11.17	GENSIGHT BIOLOGICS S.A.	145
TABLE 159	GENSIGHT BIOLOGICS SA: BUSINESS OVERVIEW	145
11.18	CELGENE CORPORATION (A BRISTOL-MYERS SQUIBB COMPANY)	146
TABLE 160	CELGENE CORPORATION: BUSINESS OVERVIEW	146
11.19	CELLECTIS	147
TABLE 161	CELLECTIS: BUSINESS OVERVIEW	147
11.20	SANGAMO THERAPEUTICS	148
TABLE 162	SANGAMO THERAPEUTICS: BUSINESS OVERVIEW	148
11.21	MUSTANG BIO	149
TABLE 163	MUSTANG BIO: BUSINESS OVERVIEW	149
11.22	AGTC (APPLIED GENETIC TECHNOLOGIES CORPORATION)	151
TABLE 164	AGTC: BUSINESS OVERVIEW	151
11.23	POSEIDA THERAPEUTICS, INC.	152
TABLE 165	POSEIDA THERAPEUTICS INC: BUSINESS OVERVIEW	152
*Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments might not be captured in case of unlisted companies.		
12	APPENDIX	153
12.1	DISCUSSION GUIDE	153
12.2	KNOWLEDGESTORE: MARKETSandMARKETS' SUBSCRIPTION PORTAL	156

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

12.3 AVAILABLE CUSTOMIZATION OPTIONS 158

12.4 RELATED REPORTS 158

12.5 AUTHOR DETAILS 159

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Gene Therapy Market by Vectors (Non-viral(Oligonucleotides), Viral(Retroviral, Adeno-associated)), Indication (Cancer, Neurological, Hepatological Diseases, Duchenne Muscular Dystrophy), Delivery Method (In Vivo, Ex Vivo), Region - Global Forecast to 2027

Market Report | 2022-07-27 | 154 pages | MarketsandMarkets

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Single User	\$4950.00
	Multi User	\$6650.00
	Corporate License	\$8150.00
	Enterprise Site License	\$10000.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Zip Code*

Country*

Date

2026-06-09

Signature

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com